Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06683534

Palmitic Acid and Human Microvascular Function

The goal of this study is to learn how a supplement Quercetin can affect microvascular function.

Participants will:

* give two blood draws of 5 mL each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion

Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Microvascular Dysfunction Body Weight Cardiovascular Diseases Cardiovascular Diseases (CVD) Microvascular Health Microvasculature Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity and Overweight Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Froedtert Hospital

Wauwatosa, Wisconsin, 53226, United States

Location contact

Julia Vogt

CONTACT

[email protected]

4149552348

Julie Freed, MD, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Obesity (BMI>30)
  • Aged 18-40 years
  • English Speaking

Exclusion criteria

  • BMI>60
  • Resting SBP ≥180 mmHg or DBP ≥ 110mmHg
  • Pregnancy or breastfeeding.
  • Prior history of myocardial infarction
  • Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)
  • Active mouth sores that affect the buccal mucosa.

Treatment and study plan

Quercetin (dietary supplement)

Dietary Supplement

Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.

Placebo

Drug

Subjects randomized to receive placebo will be administered a standard placebo sugar pill.

Primary outcomes

  1. Change in blood vessel dilation

    Time frame: 2 hours

    Peripheral microvascular dilation in response to acetylcholine, L-NAME, and sodium nitroprusside infusions will be measured using laser Doppler flowmetry with microdialysis.

Secondary outcomes

  1. Change in Perfused Vessel Density

    Time frame: 0.5 hours

    Total vessel density (TVD) will be calculated using the DeBacker Score manual analysis on all images that have a minimum microcirculation image quality score (MIQS) of 10. Perfused vessel density (PVD) will be calculated by multiplying total vessel density (TVD) x proportion of perfused vessels (PPV%).

Study contacts

Contact information is provided by the study sponsor or research team.

Julia A Vogt

CONTACT

[email protected]

4149552348

Sponsors and collaborators

Lead sponsor

Medical College of Wisconsin

Other

Registry information

Official study title

Use of Quercetin to Increase Resiliency to Palmitic Acid in the Human Microvasculature

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Nov 12, 2024
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.